Trial Profile

A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis - M1095-axSpA-202

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonelokimab (Primary)
Indications Axial spondyloarthritis
Focus Proof of concept; Therapeutic Use
Acronyms M1095-axSpA-202; S-OLARIS
Sponsors MoonLake Immunotherapeutics

Most Recent Events

22 Feb 2026 Primary endpoint has been met. (Change from baseline in 18F-NaF SUVmax signals at Week 12 in the sacroiliac joints (SIJ) and spine as detected by PET scan.)
22 Feb 2026 Results presented in the MoonLake Immunotherapeutics Media Release.
02 Feb 2026 According to a MoonLake Immunotherapeutics media release, primary endpoint readout of the trial is anticipated in February 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com